SG11202111066UA - High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy - Google Patents

High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy

Info

Publication number
SG11202111066UA
SG11202111066UA SG11202111066UA SG11202111066UA SG11202111066UA SG 11202111066U A SG11202111066U A SG 11202111066UA SG 11202111066U A SG11202111066U A SG 11202111066UA SG 11202111066U A SG11202111066U A SG 11202111066UA SG 11202111066U A SG11202111066U A SG 11202111066UA
Authority
SG
Singapore
Prior art keywords
lipoprotein
high density
nanoparticles
ocular therapy
particles
Prior art date
Application number
SG11202111066UA
Other languages
English (en)
Inventor
C Thaxton
Robert Lavker
Kaylin Mcmahon
Han Peng
Andrea Calvert
Nihal Kaplan
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of SG11202111066UA publication Critical patent/SG11202111066UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202111066UA 2019-04-26 2020-04-24 High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy SG11202111066UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839579P 2019-04-26 2019-04-26
PCT/US2020/029752 WO2020219833A1 (en) 2019-04-26 2020-04-24 High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy

Publications (1)

Publication Number Publication Date
SG11202111066UA true SG11202111066UA (en) 2021-11-29

Family

ID=72940657

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111066UA SG11202111066UA (en) 2019-04-26 2020-04-24 High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy

Country Status (9)

Country Link
US (1) US20220211633A1 (zh)
EP (1) EP3958843A4 (zh)
JP (1) JP2022529506A (zh)
CN (1) CN113939278A (zh)
AU (1) AU2020261414A1 (zh)
CA (1) CA3137565A1 (zh)
MX (1) MX2021013068A (zh)
SG (1) SG11202111066UA (zh)
WO (1) WO2020219833A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091065A2 (en) 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
AU2022296780A1 (en) * 2021-06-22 2023-12-07 Bio-Trip B.V. Nucleic acid containing nanoparticles
KR20240037272A (ko) * 2021-07-09 2024-03-21 주식회사 루카에이아이셀 건조 예방, 개선 또는 치료를 위한 지질 혼합물을 함유하는 점안액 및 이의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
JP5539962B2 (ja) * 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ コレステロールを隔離するのに適したナノ構造体
WO2011091065A2 (en) * 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
WO2012078558A2 (en) * 2010-12-06 2012-06-14 Rush University Medical Center microRNAs AS NEW THERAPEUTIC TARGETS FOR THE PREVENTION AND/OR TREATMENT OF RETINOPATHY
CA2865279C (en) * 2012-02-22 2023-04-25 Northwestern University Nanostructures for treating cancers and other conditions
EP3238746B1 (en) * 2014-12-25 2023-12-20 Kyoto University High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
US20170165200A1 (en) * 2015-11-20 2017-06-15 University Of North Texas Health Science Center Composition of lipid-based nanoparticles for small molecules and macromolecules
US10967072B2 (en) * 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
CN110087638A (zh) * 2016-12-14 2019-08-02 中国医药大学 微小rna-195组合物及其在眼科疾病中的应用

Also Published As

Publication number Publication date
MX2021013068A (es) 2022-01-24
WO2020219833A1 (en) 2020-10-29
CN113939278A (zh) 2022-01-14
EP3958843A4 (en) 2023-02-22
US20220211633A1 (en) 2022-07-07
EP3958843A1 (en) 2022-03-02
CA3137565A1 (en) 2020-10-29
AU2020261414A1 (en) 2021-11-04
JP2022529506A (ja) 2022-06-22

Similar Documents

Publication Publication Date Title
SG11202111066UA (en) High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy
GB2605540B (en) Tumor infiltrating lymphocytes and methods of therapy
ZA201907158B (en) Methods and compositions for treating sleep apnea
EP3270994A4 (en) Methods and apparatus for ventilatory treatment of respiratory disorders
IL277713A (en) Implantable particles and related methods
SG11202101619UA (en) Therapeutic nanoparticles and methods of use thereof
IL276247A (en) Methods and materials for the treatment of sleep apnea
EP3442578A4 (en) METHOD FOR DETERMINING AND OBTAINING THERAPEUTICALLY ACTIVE DOSES OF ANTI-CD47 MEDIUM IN THE TREATMENT OF CANCER
EP3538075A4 (en) GENE THERAPY STRUCTURES AND PROCESSES
EP3634431A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT FOR HEPATITIS B
IL285197A (en) Methods and preparations for the treatment of sleep apnea
IL261729B (en) A method for preparing viral particles with a cyclic dinucleotide and using those particles for cancer treatment
ZA201901910B (en) Therapeutic protein-loaded nanoparticle and method for preparing the same
EP3589344A4 (en) SOUND ATTENUATION STRUCTURES AND METHODS FOR USE IN THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA
EP3117438A4 (en) Method and apparatus of confining high energy charged particles in magnetic cusp configuration
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
EP3541458A4 (en) METHODS AND APPARATUS FOR VENTILATION TREATMENT OF RESPIRATORY DISORDERS
EP3360580A4 (en) METHOD FOR THE GENETIC TREATMENT USED BY AAV XBP1S / GFP VIRUS AND USE THEREOF IN THE PREVENTION AND TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS
EP3400008A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B
IL294066A (en) Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
SG10202100422VA (en) Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy
EP3439685A4 (en) METHODS OF TREATING CANCER AND INFECTIOUS DISEASES USING CELL-BASED THERAPIES
EP2777660A4 (en) METHOD FOR PREVENTING THE APPEARANCE AND PROGRESSION OF MYOPIA
IL279480A (en) A method for in vitro differentiation and maturation of dendritic cells for therapeutic use
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease